IL113912A - Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders - Google Patents

Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders

Info

Publication number
IL113912A
IL113912A IL11391295A IL11391295A IL113912A IL 113912 A IL113912 A IL 113912A IL 11391295 A IL11391295 A IL 11391295A IL 11391295 A IL11391295 A IL 11391295A IL 113912 A IL113912 A IL 113912A
Authority
IL
Israel
Prior art keywords
methyl
benzodiazepine
thieno
piperazinyl
treatment
Prior art date
Application number
IL11391295A
Other languages
English (en)
Other versions
IL113912A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL113912A0 publication Critical patent/IL113912A0/xx
Publication of IL113912A publication Critical patent/IL113912A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL11391295A 1994-06-03 1995-05-29 Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders IL113912A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/253,658 US5457101A (en) 1994-06-03 1994-06-03 Thieno[1,5]benzoidiazepine use

Publications (2)

Publication Number Publication Date
IL113912A0 IL113912A0 (en) 1995-08-31
IL113912A true IL113912A (en) 1999-04-11

Family

ID=22961179

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11391295A IL113912A (en) 1994-06-03 1995-05-29 Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders

Country Status (14)

Country Link
US (1) US5457101A (xx)
EP (1) EP0685233B1 (xx)
JP (1) JPH07330608A (xx)
KR (1) KR960000229A (xx)
CN (1) CN1119101A (xx)
AU (1) AU684924B2 (xx)
CA (1) CA2150517A1 (xx)
DE (1) DE69528109D1 (xx)
HU (1) HUT71598A (xx)
IL (1) IL113912A (xx)
NO (1) NO306977B1 (xx)
NZ (1) NZ272231A (xx)
TW (1) TW372872B (xx)
ZA (1) ZA954358B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5981523A (en) * 1996-02-05 1999-11-09 Eli Lilly And Company Compounds and methods for treating multiple sclerosis
JP2000506860A (ja) * 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 自閉症の処置方法
AU734011B2 (en) * 1996-03-11 2001-05-31 Eli Lilly And Company Method for treating bipolar disorder
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
CN1219878A (zh) * 1996-03-25 1999-06-16 伊莱利利公司 治疗疼痛的方法
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
JP2002530339A (ja) 1998-11-23 2002-09-17 セプラコール， インク． ２−ヒドロキシメチルオランザピン組成物及び方法
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
UA80095C2 (en) * 2001-07-20 2007-08-27 Lilly Co Eli 2 methyl-thieno-benzodiazepine lyophilized formulation and method for the preparation thereof
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
GB0207091D0 (en) * 2002-03-26 2002-05-08 Ml Lab Plc Method of treatment
US7407788B2 (en) * 2002-11-21 2008-08-05 Danisco A/S, Genencor Division BGL7 beta-glucosidase and nucleic acids encoding the same
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
WO2005070938A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2012051502A1 (en) 2010-10-14 2012-04-19 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
EP3497105A1 (en) * 2016-08-11 2019-06-19 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
NZ247703A (en) * 1992-05-29 1995-07-26 Lilly Industries Ltd Thienobenzdiazepine derivatives and medicaments thereof
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
CA2185236A1 (en) * 1994-03-11 1995-09-14 James Edmund Audia Method for treating 5ht2b receptor related conditions

Also Published As

Publication number Publication date
NO306977B1 (no) 2000-01-24
DE69528109D1 (de) 2002-10-17
JPH07330608A (ja) 1995-12-19
NZ272231A (en) 2001-05-25
HU9501600D0 (en) 1995-07-28
ZA954358B (en) 1996-11-29
EP0685233A3 (en) 1996-04-03
EP0685233B1 (en) 2002-09-11
IL113912A0 (en) 1995-08-31
AU2042495A (en) 1995-12-14
EP0685233A2 (en) 1995-12-06
CA2150517A1 (en) 1995-12-04
NO952130D0 (no) 1995-05-30
CN1119101A (zh) 1996-03-27
TW372872B (en) 1999-11-01
KR960000229A (ko) 1996-01-25
US5457101A (en) 1995-10-10
NO952130L (no) 1995-12-04
AU684924B2 (en) 1998-01-08
HUT71598A (en) 1996-01-29

Similar Documents

Publication Publication Date Title
IL113912A (en) Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
HUP9802824A3 (en) Novel crystal form of the 2-methyl-4-(4-methyl-1-piprezinyl)-10h-thieno[2,3-b][1,5]benzodiazepine and process for its preparation
GB2292079B (en) Coated prednisolone preparation for the treatment of inflamatory bowel disease
AP9500731A0 (en) 1,5 benzodiazepine derivatives
ZA936872B (en) 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-B]heterocyclic-2-one useful in the treatment of cognitive disorders of man
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
GB2311779B (en) 2,3 benzodiazepine derivatives
PL327539A1 (en) 2,7-substituted derivatives of octahydropyrrole[1,2-a]-pyrazine
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AP9801275A0 (en) Use of tricyclic 1,4-dihydro-1,4-dioxo-1H-naphthalene derivatives resulting novel compounds and therapeutical use thereof
GB9419048D0 (en) Treatment of muscular disorders
HUP9903688A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating autism
IL119868A0 (en) Process for the preparation of 4,4'-oxybisphthalic dianhydride
IL119744A0 (en) Use of 8,9-dehydroestrone
GR3035910T3 (en) Derivatives of 10,11-dihydro-10-oxo-5h-dibenz/b,f/azepine-5-carboxamide
IL136949A0 (en) 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
IL120285A (en) Process for the preparation of 1,5-benzothiazepine derivatives, process for the preparation of the intermediate thereof and an intermediate thereof
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
IL113398A0 (en) Use of N-isobutyl-N'-isopropyl - 9,9- pentamethylene - 3,7 - diazabicyclo [3,3,1] nonane
ZA957309B (en) New thiazolo[3,2-a]quinoline and -naphthyridine derivatives
ZA95511B (en) Treatment of anorectal disorders
ZA953056B (en) 1,5 benzodiazepine derivatives
GB9406037D0 (en) 1,5 Benzodiazepine derivatives
SI1069900T1 (sl) Uporaba reboksetina za zdravljenje nevropsihiatricnih motenj

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees